Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.
Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, Markman B, McDonald F, Mornex F, Moskovitz M, Peters S, Sibille A, Siva S, van den Heuvel M, Vercauter P, Anand S, Chander P, Licour M, de Lima AR, Qiao Y, Girard N.
Filippi AR, et al. Among authors: de lima ar.
ESMO Open. 2024 Jun;9(6):103464. doi: 10.1016/j.esmoop.2024.103464. Epub 2024 Jun 3.
ESMO Open. 2024.
PMID: 38833971
Free PMC article.